New International CTEPH Database
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02656238 |
Recruitment Status :
Completed
First Posted : January 14, 2016
Last Update Posted : August 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The New International CTEPH Database is a prospective, observational multi-center disease registry run by the International CTEPH Association (ICA), which will collect data in chronic thromboembolic pulmonary hypertension (CTEPH) patients worldwide. The registry will run for approximately 5 years. Its objective is to provide an overview on epidemiology of CTEPH, mode of diagnosis and treatment approaches worldwide as well as determinants of long-term outcomes as measured by New York Heart Association (NYHA) functional class and survival.
The data collected will improve the knowledge and understanding of this condition, support the further development of diagnosis and treatment guidelines for patients with CTEPH, and contribute to improving patient care in the long-term.
Condition or disease |
---|
Chronic Thromboembolic Pulmonary Hypertension CTEPH |
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 1019 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 3 Years |
Official Title: | New International CTEPH Database |
Study Start Date : | February 2015 |
Actual Primary Completion Date : | January 2020 |
Actual Study Completion Date : | January 2020 |

- Death [ Time Frame: Min. 3 years ]
- Lung transplantation [ Time Frame: Min. 3 years ]
- Change in New York Heart Association (NYHA) functional class [ Time Frame: Min 3. years ]
- Age at diagnosis [ Time Frame: Min. 3 years ]
- Gender [ Time Frame: Min. 3 years ]
- Ethnicity [ Time Frame: Min. 3 years ]
- Disease severity [ Time Frame: Min. 3 years ]As measured by New York Heart Association (NYHA) functional class
- History of deep vein thrombosis (DVT) [ Time Frame: Min. 3 years ]
- History of acute pulmonary embolism [ Time Frame: Min. 3 years ]
- Hemodynamic parameters [ Time Frame: Min. 3 years ]
- Patient on oxygen (yes/no) [ Time Frame: Min. 3 years ]
- Medical treatment [ Time Frame: Min. 3 years ]e.g. mono- versus combination therapy
- Pulmonary endarterectomy (PEA) [ Time Frame: Min. 3 years ]e.g. operated versus non-operated
- Balloon pulmonary angioplasty (BPA) [ Time Frame: Min. 3 years ]e.g. BPA versus pulmonary endarterectomy (PEA)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients recently diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), meeting the registry's inclusion criteria, are eligible for inclusion into the New International CTEPH Database.
Only newly diagnosed, i.e. incident patients are eligible for inclusion. A patient is considered an incident patient if a diagnostic heart catheterization was performed within 1 year prior to the initial inclusion visit (for the first patient included) at the site participating in the New International CTEPH Database.
Inclusion Criteria:
- Patients must be newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) (incident patients)
- Patients must have been treated with anti-coagulation for at least 3 months before diagnosis of CTEPH
- Patients must be willing to provide informed consent
-
Patients must meet the following criteria for CTEPH:
- Mean pulmonary artery pressure (PAP) ≥ 25 mmHg at rest
- Abnormal VQ scan, pulmonary angiogram, computed tomography (CT) pulmonary angiogram, or magnetic resonance (MR) pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
Exclusion Criteria:
- None specified

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02656238

Publications of Results:
Responsible Party: | International CTEPH Association |
ClinicalTrials.gov Identifier: | NCT02656238 |
Other Study ID Numbers: |
CTEPH Registry |
First Posted: | January 14, 2016 Key Record Dates |
Last Update Posted: | August 8, 2022 |
Last Verified: | August 2022 |
CTEPH Balloon pulmonary angioplasty Chronic thromboembolic pulmonary hypertension |
Pulmonary endarterectomy BPA PEA |
Hypertension, Pulmonary Hypertension Vascular Diseases |
Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |